Aptinyx Inc. (APTX)
(Delayed Data from NSDQ)
$3.78 USD
+0.03 (0.80%)
Updated May 3, 2019 04:00 PM ET
After-Market: $3.79 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
[APTX]
Reports for Purchase
Showing records 1 - 20 ( 72 total )
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
NYX-458 Phase 2 Failure; Downgrading to Neutral Without a PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Gradual Pipeline Progress; 3Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
NYX-458 Enrollment Done; NYX-2925 Clinical Failure; Lowering PT to $1
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Catalyst-Rich Period Approaching; 2Q22 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Data Readouts Could Revive Interest; 1Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
NYX-2925 Fails in Diabetic Peripheral Neuropathy; Lowering PT to $2
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Investors Were on Pins & Needles for NYX-2925/DPN Data, But Trial Misses
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Data Catalysts Approaching; 2021 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
NYX-2925 Phase 2b Fibromyalgia Trial Completes Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
NYX-783 Post-Traumatic Stress Disorder Pivotal Program Initiated; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Rolling Right Along With Steady Lineup of Readouts in FY22
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Industry: Medical - Biomedical and Genetics
3Q21 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Clinical Programs Advancing; 2Q21 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R